7V0P image
Deposition Date 2022-05-10
Release Date 2023-04-05
Last Version Date 2024-10-16
Entry Detail
PDB ID:
7V0P
Title:
Cryo-EM structure of SINV/EEEV in complex with Fab fragment of a potently neutralizing human antibody IgG-106
Biological Source:
Source Organism:
Host Organism:
Method Details:
Experimental Method:
Resolution:
5.20 Å
Aggregation State:
PARTICLE
Reconstruction Method:
SINGLE PARTICLE
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:Spike glycoprotein E1
Chain IDs:A, B, C, D
Chain Length:342
Number of Molecules:4
Biological Source:Eastern equine encephalitis virus
Polymer Type:polypeptide(L)
Molecule:IgG 106 Fab heavy chain
Chain IDs:E, G, I, K
Chain Length:229
Number of Molecules:4
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:IgG 106 Fab light chain
Chain IDs:F, H, J, L
Chain Length:212
Number of Molecules:4
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:Spike glycoprotein E2
Chain IDs:M (auth: a), N (auth: b), O (auth: c), P (auth: d)
Chain Length:342
Number of Molecules:4
Biological Source:Eastern equine encephalitis virus
Ligand Molecules
Primary Citation
Structural constraints link differences in neutralization potency of human anti-Eastern equine encephalitis virus monoclonal antibodies.
Proc.Natl.Acad.Sci.USA 120 e2213690120 e2213690120 (2023)
PMID: 36961925 DOI: 10.1073/pnas.2213690120

Abstact

Selection and development of monoclonal antibody (mAb) therapeutics against pathogenic viruses depends on certain functional characteristics. Neutralization potency, or the half-maximal inhibitory concentration (IC50) values, is an important characteristic of candidate therapeutic antibodies. Structural insights into the bases of neutralization potency differences between antiviral neutralizing mAbs are lacking. In this report, we present cryo-electron microscopy (EM) reconstructions of three anti-Eastern equine encephalitis virus (EEEV) neutralizing human mAbs targeting overlapping epitopes on the E2 protein, with greater than 20-fold differences in their respective IC50 values. From our structural and biophysical analyses, we identify several constraints that contribute to the observed differences in the neutralization potencies. Cryo-EM reconstructions of EEEV in complex with these Fab fragments reveal structural constraints that dictate intravirion or intervirion cross-linking of glycoprotein spikes by their IgG counterparts as a mechanism of neutralization. Additionally, we describe critical features for the recognition of EEEV by these mAbs including the epitope-paratope interaction surface, occupancy, and kinetic differences in on-rate for binding to the E2 protein. Each constraint contributes to the extent of EEEV inhibition for blockade of virus entry, fusion, and/or egress. These findings provide structural and biophysical insights into the differences in mechanism and neutralization potencies of these antibodies, which help inform rational design principles for candidate vaccines and therapeutic antibodies for all icosahedral viruses.

Legend

Protein

Chemical

Disease

Primary Citation of related structures